Esperion Therapeutics Inc

Esperion Secures Patent Protection for NEXLETOL Until 2040 Through Settlement with Micro Labs

10 days ago

• Esperion Therapeutics has reached a settlement agreement with Micro Labs that prevents the generic manufacturer from marketing a version of NEXLETOL (bempedoic acid) before April 19, 2040. • The agreement resolves patent litigation initiated by Esperion in response to Micro Labs' Abbreviated New Drug Application seeking approval for a generic version of the cholesterol-lowering medication. • Litigation against eight other ANDA filers continues, with no guarantee that these ongoing cases will prevent other generic versions from entering the market before the 2040 patent expiration.

Esperion Files for Canadian Approval of Nexletol and Nexlizet for LDL-C Reduction and Cardiovascular Risk

6 months ago

• Esperion has submitted New Drug Submissions (NDSs) in Canada for Nexletol and Nexlizet, seeking approval for LDL-C reduction and cardiovascular risk management. • Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) are oral, non-statin medications already approved in the United States and Europe. • Heart disease is a leading cause of death in Canada, affecting approximately 2.6 million adults, highlighting the need for new treatment options. • The submissions are based on data, including the CLEAR outcomes study, supporting the drugs' efficacy in reducing cardiovascular risk and LDL-C levels.

Esperion Therapeutics Reports Increased Revenue and Reduced Net Loss in Q3 2024

6 months ago

• Esperion Therapeutics reports a net product revenue increase of $10.8 million compared to Q3 2023, driven by prescription growth of NEXLETOL and NEXLIZET. • The company's R&D expenses decreased by $4.5 million due to the completion of the CLEAR Outcomes study, contributing to a reduced net loss of $29.5 million. • Esperion anticipates that current cash resources, expected future net product sales, and revenue under collaboration agreements will be sufficient to fund operations for the foreseeable future.